Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGN4659 + Cemiplimab in Advanced NSCLC
NCT03580694Phase 1Terminated
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jun 2018
- Primary completion
- Dec 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of REGN4659 in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Rate of dose limiting toxicities, Rate of treatment emergent adverse events and 6 more. Started Jun 2018; status: terminated.
02
Drugs
REGN4659
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03580694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03580694.